Introduction {#s1}
============

Insulin resistance (IR) is a pathological condition in which target tissues (primarily skeletal muscle, liver, and adipose tissue) have an impaired biological response to insulin stimulation. During IR, the body's compensatory release of excess insulin to maintain blood sugar stability causes hyperinsulinemia that can progress to type 2 diabetes mellitus (T2D). Prospective studies have highlighted the importance of IR in the pathogenesis of T2D and suggest that IR is the best predictor of future T2D diagnosis ([@B135]). IR and obesity are connected with chronic inflammation in metabolic tissues such as adipose tissue and the liver ([@B232]). Some studies have pointed out that body mass index is positively associated with IR ([@B133]) and inflammation in visceral adipose tissue is a main driver of IR ([@B146]). Closely linked to the epidemic of obesity ([@B167]), the number of adults with diabetes increased from 108 million in 1980 to 422 million in 2014 ([@B270]), and this figure is projected to rise to 642 million people by 2040. There are many vascular and nerve-related complications in diabetes such as diabetes-induced dysregulation of cardiac function, instability of microvasculature of the heart, and increased risk for heart failure ([@B188]; [@B125]; [@B72]). The risk of dementia, Alzheimer's disease, and cognitive decline are elevated in people with IR ([@B21]; [@B231]; [@B116]) and T2D; the global prevalence of diabetic foot pathologies is 6.3%, and 12.9 to 49.0 million people worldwide have a history of foot ulceration ([@B9]; [@B260]). These complications bring a tremendous medical and socioeconomic burden. IR is associated with increased risk for other associated disorders, including polycystic ovary syndrome (PCOS), hepatitis C virus, nonalcoholic fatty liver disease (NAFLD), and metabolic syndrome ([@B44]; [@B157]; [@B12]). Improving IR may provide a therapeutic strategy for controlling T2D, obesity, and many other diseases. Current interventions for IR include intensive lifestyle interventions, thiazolidinedione, DPP-4 inhibitors, and metformin. However, IR is not well controlled and poses a threat to modern society ([@B102]). Some herbal medicines such as *Coptis chinensis* Franch ([@B268]), *Ganoderma lucidum*, and *Panax ginseng* C. A. Mey result in enhanced insulin sensitivity through modulation of diverse physiological and cellular pathways ([@B27]; [@B152]; [@B14]). For centuries, natural herbs and herbal formulae derived from systemic traditional Chinese medicine theory and practice have been used to treat many kinds of ailments in China. At present, Chinese medicine has received strong support from the World Health Organization and will be included in Chapter 26 of the 11th edition of the Global Medical Program. Chinese medicine also provides treatments for obesity and T2D ([@B39]). In the third century BC, *Huang Di Nei Jing*, the most classic book of Chinese medicine, recorded similar diseases related to diabetes and obesity and provided treatment principles. Now, traditional Chinese medicine is widely used to clinically treat IR. In this review, we explored whether herbs and their formulations or monomers can improve IR and the mechanisms of herbal compounds that increase insulin sensitivity.

Methodology {#s2}
===========

According to the Pharmacopoeia of the People's Republic of China that was revised by the China Food and Drug Administration in 2015, herbal medicine is defined as therapy using herbs and materials derived from botanical herbal products and mineral and animal sources. Interventions that were used in this study include single-flavored herbs and their extracts, active ingredients, and herbal formulas. There were no geographical restrictions on the herbs included.

We reviewed literature (from PubMed) published between July 8, 2013 and July 6, 2018 on IR that had been treated with herbal medicine. The following combination of terms were used as search keywords: "herbal," "phytochemical," "phytomedicine," "natural product," and "insulin resistance" or "IR." The search did not exclude articles based on language or status of the publication.

The specified exclusion criteria include: a) case reports, case series, editorials, reviews; b) interventions containing ingredients other than herbs; and c) relevant indicators of IR, such as homeostatic model assessment of IR (HOMA-IR), and IR-index, not involved in the primary and secondary outcomes of clinical trials.

Results {#s3}
=======

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow chart ([**Figure 1**](#f1){ref-type="fig"}) of article processing shows that our search yielded 1,363 articles, and 1,007 articles were excluded based on the exclusion criteria. After excluding these 1,007 articles, we included 137 articles, including 36 clinical trials, 58 *in vivo* experiments, 20 *in vitro* experiments, and 23 that were a combination of both *in vitro* and *in vivo* experiments. Based on further reading of this literature, we divided 101 *in vivo* and *in vitro* experiments into three parts based on the interventional drug used: active ingredients (31 articles), natural products (38 articles), and herbal formulas (32 articles). The results suggest that most clinical trials (30 articles) indicate that herbal active ingredients, natural products, and herbal formulas, such as JTTZ formula, Jinlida, and Curcumin, have a therapeutic effects on IR. There were a few clinical trials (six articles) that did not support the above results, such as those that used marjoram tea, hydroalcoholic extract of *Juglans regia* (walnut) leaves, *Fraxinus excelsior* L. seeds/fruit extract, garlic extract, bee propolis, red wine polyphenols. On the other hand, we concluded that the effects of herbal medicine on IR may be related to 11 important target molecules that affect insulin signaling, such as insulin receptor substrate, phosphatidylinositol 3-kinase, and glucose transporter.

![PRISMA 2019 Flow Diagram.](fphar-10-00661-g001){#f1}

Clinical Trials to Improve Insulin Resistance {#s3_1}
---------------------------------------------

In clinical trials, participants in the treatment group should be restricted to using herbs alone. If medication other than herbs are being used, then the medication must be administered to both the treatment group and the control group. Participants in the control group should receive hypoglycemic agents, placebo, or life interventions. There is no limit to the number of predetermined herbs, recipes, sample sizes, or duration of treatment.

IR can be accurately assessed by clinical examination. It is generally believed that hyperinsulinemic-euglycemic clamps are the "gold standard" for determining IR, but the complex nature and inherent potential hazards of this technique limit its routine use ([@B177]). Commonly used alternatives are primarily HOMA-IR and quantitative insulin sensitivity check index (QUICKI), which use fasting insulin and glucose concentrations to assess IR and correlate with the results of the clamp study ([@B156]). In the 36 clinical trials ([**Table 1**](#T1){ref-type="table"}) in the above table, most of the drugs examined were herbal formulas, including herbal extracts and active ingredients, and the diseases of concern included T2D, metabolic syndrome, obesity, impaired glucose tolerance, PCOS, and cirrhosis. Most studies have shown that herbal medicine can not only reduce IR but also improve blood sugar, blood lipids, glycosylated hemoglobin, and other biochemical indicators. Indicators of IR in these studies include HOMA-IR, QUICKI, area under the curve of insulin, and IR index. Among them, HOMA-IR was the indicator and was used in 29 studies (29/36, 80%). In order to objectively observe the therapeutic effect of herbs on IR, the changes in IR evaluation indicators before and after treatment in 36 clinical trials are listed in [**Table 2**](#T2){ref-type="table"}.

###### 

Clinical trials related to insulin resistance.

  Compounds/formula                                           Design   Disease                                           Dose regimen            Duration               Case/control   Main outcome\*                                                                                                                                                  Side effect               Reference
  ----------------------------------------------------------- -------- ------------------------------------------------- ----------------------- ---------------------- -------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------- -----------
  JTTZ Formula                                                RCT      type 2 diabetic mellitus                          0.25g po bid            12 weeks               215/199        HbA1c ↓, T ↓, weight ↓, HOMA-IR ↓                                                                                                                               not mentioned             ([@B254])
  Tangyiping Granules (TYP)                                   RCT      impaired glucose tolerance                        10g po bid              3, 12, and 24 months   60/60          NGT ↑, 2hPG ↓, HbA1c ↓, HOMA-IR ↓, TG ↓                                                                                                                         not mentioned             ([@B85])
  Jinlida (JLD)                                               RCT      impaired glucose tolerance                        one bag po tid          12 weeks               32/29          HbA1c ↓, 2hPG ↓, HOMA-IR ↓                                                                                                                                      no side effect is found   ([@B206])
  Qingxue Dan (QXD)                                           RCT      obesity                                           900mg po qd             8 week                 13/13          BMI ↓, TG ↓, WC ↑, total cholesterol ↑, high-density lipoprotein cholesterol ↑, HOMA-IR ↓                                                                       not mentioned             ([@B36])
  Artemisia dracunculus                                       RCT      impaired glucose tolerance                        1000mg po bid           90 days                12/12          HbA1c ↓, AUC of insulin ↓, total insulin secretion ↓, HDL-C ↑, SBP ↓                                                                                            not mentioned             ([@B158])
  Qingre Yangyin Recipe (QRYYR)                               RCT      polycystic ovary syndrome                         one dose po bid         3 months               30/30          BMI ↓, FINS ↓, 2h INS ↓, HOMA-IR ↓, leptin ↓, LH ↓, PRL ↓, T ↓, APN ↑, FPG ↓, 2 hPG ↓                                                                           not mentioned             ([@B261])
  Sancaijiangtang powders                                     RCT      type 2 diabetic mellitus and vascular dementia    powders po tid          12 weeks               84/84          fasting plasma glucose ↓, fasting insulin ↓, HbA1c ↓, HOMA-IR ↓, plasma nitric oxide ↓, endothelin-1 ↓                                                          not mentioned             ([@B181])
  Cinnamon                                                    RCT      type 2 diabetic mellitus                          1g po qd                90 days                35/35/35       FPG ↓, 2h PG ↓, HOMA-IR ↓,                                                                                                                                      not mentioned             ([@B162])
  Jinlida                                                     RCT      type 2 diabetic mellitus                          9g po tid+ metformin    12 weeks               92/94          HbA1c ↓, FG ↓, 2h PG ↓, HOMA-β ↑, HOMA-IR ↓                                                                                                                     not mentioned             ([@B134])
  Zhenggan Tang decoction                                     RCT      HBV-induced cirrhotic                             125ml po bid            3 months               35/31          leptin ↓, adiponectin ↓, IR-index ↓                                                                                                                             not mentioned             ([@B240])
  Marjoram tea                                                RCT      polycystic ovary syndrome                         1.3--1.5g po bid        1 month                14/11          DHEA-S ↓, fasting insulin levels ↓, HOMA-IR was not reduced significantly                                                                                       not mentioned             ([@B64])
  xin-ju-xiao-gao-fang (XJXGF)                                RCT      obesity                                           170ml po bid            24 weeks               59/55          IR-index ↓, weight ↓                                                                                                                                            not mentioned             ([@B271])
  Yiqi Huaju Recipe (YHR)                                     RCT      hypertension patients with metabolic syndrome     17.5g po bid            12 weeks               22/21          WC ↓, WHR ↓, 2h PG ↓, FPI ↓, HOMA-IR ↓, average blood pressure amplitude ↑, blood pressure variability ↑, blood pressure load ↑                                 not mentioned             ([@B30])
  Ginger (GG)                                                 RCT      type 2 diabetic mellitus                          1g po tid               8 weeks                40/41          FBS ↓, HbA1c ↓, HOMA-IR ↓, S% ↑, QUICKI ↑                                                                                                                       not mentioned             ([@B164])
  Curcumin                                                    RCT      type 2 diabetic mellitus                          three capsules po bid   6 months               120/120        pulse wave velocity ↓, adiponectin ↑, leptin ↓, HOMA-IR ↓, TG ↓, uric acid ↓, visceral fat ↓, total body fat ↓                                                  no side effect is found   ([@B35])
  Hydroalcoholic extract of *Juglans regia* (walnut) leaves   RCT      type 2 diabetic mellitus                          100mg po qd             8 weeks                20/20          weight ↓, body mass index ↓, systolic blood pressure ↓, no significant effect on blood glucose level and HOMA-IR                                                no side effect is found   ([@B183])
  Yangxin Tongmai Formula (YTF)                               RCT      Graves' disease with impaired glucose tolerance   50ml po tid             60 days                20/20          ISI ↓, HOMA-IR ↓, insulin receptor ↑, plasma insulin levels ↓                                                                                                   not mentioned             ([@B149])
  Sancai powder                                               RCT      type 2 diabetic mellitus                          200 ml po bid           12 weeks               47/49          HbA1c ↓, FPG ↓, 2hPG ↓, TG ↓, HOMA-β ↓, HOMA-IR ↓, ISI ↓                                                                                                        not mentioned             ([@B61])
  *Fraxinus excelsior* L. seeds/fruits extract                RCT      non-diabetic overweight/obese                     1g po tid               7 weeks                11/6           AUC of insulin ↓, 2hPG ↓, adiponectin: Leptin ratio ↑, fat mass ↓, serum fructosamine ↓, plasma glucagon ↑, no significant changes IR-index and Matsuda Index   no side effect is found   ([@B276])
  Berberine                                                   RCT      metabolic syndrome                                500mg po tid            3 months               12/12          WC ↓,SBP ↓,TG ↓, AUC of insulin ↓, AUC of glucose ↓, insulinogenic index ↓,Matsuda index ↑                                                                      no side effect is found   ([@B180])
  Aloe vera gel complex                                       RCT      obese prediabetes                                 1400mg po bid           8 weeks                60/62          weight ↓, HOMA-IR ↓, FBG ↓, serum insulin level ↓                                                                                                               not mentioned             ([@B33])
  Green tea extract                                           RCT      type 2 diabetes                                   500mg po tid            16 weeks               39/38          triglyceride ↓, high density lipoprotein cholesterol ↑, HOMA-IR ↓, Adiponectin ↑, apolipoprotein A1 ↑, apolipoprotein B100 ↑                                    no side effect is found   ([@B136])
  Cinnamon                                                    RCT      nonalcoholic fatty liver disease                  750mg po bid            12 weeks               23/22          HOMA-IR ↓, FBS ↓, total cholesterol ↓, triglyceride ↓, ALT ↓, AST ↓,                                                                                            not mentioned             ([@B10])
  Soybean leaf extracts (SLEs)                                RCT      prediabetes                                       2g po qd                12 weeks               15/15          FBG ↓, HbA1c ↓, HOMA-IR ↓                                                                                                                                       no side effect is found   ([@B34])
  Nigella sativa                                              RCT      type 2 diabetes mellitus                          2g po qd                12 months              57/57          FBG ↓, HbA1c ↓, HOMA-IR ↓                                                                                                                                       no side effect is found   ([@B99])
  Chamomile tea                                               RCT      type 2 diabetes mellitus                          3g po tid               8 weeks                32/32          serum insulin levels ↓, HbA1c ↓, HOMA-IR ↓, total cholesterol ↓, triglyceride ↓                                                                                 not mentioned             ([@B184])
  DLBS3233                                                    RCT      impaired glucose tolerance                        100mg po qd             12 weeks               38/36          HOMA-IR ↓                                                                                                                                                       no side effect is found   ([@B151])
  Garlic extract                                              RCT      type 2 diabetes mellitus                          1200mg po qd            4 weeks                13/13          no significant changes in weight, SBP, DBP, total cholesterol, plasma HDL cholesterol, plasma triglycerides, HOMA-IR                                            indigestion               ([@B11])
  Bee propolis                                                RCT      type 2 diabetes mellitus                          300mg po tid            12 weeks               30/27          no significant difference in HOMA-IR                                                                                                                            no side effect is found   ([@B196])
  Artemisia Extract                                           RCT      gestational Diabetes Mellitus                     400mg po qd             10 weeks               64/65          FPG ↓, serum insulin levels ↓, HOMA-IR ↓                                                                                                                        not mentioned             ([@B211])
  Red wine polyphenols                                        RCT      obesity                                           300mg po bid            8 weeks                14/15          no significant changes in HOMA-IR, LDL, HDL cholesterol or triglyceride levels                                                                                  no side effect is found   ([@B234])
  Fresh yellow onion                                          RCT      breast cancer                                     30∼40g po qd            8 weeks                23/23          FPG ↓, serum insulin levels ↓, HOMA-IR ↓                                                                                                                        no side effect is found   ([@B88])
  Gymnema sylvestre                                           RCT      metabolic syndrome                                300mg po bid            12 weeks               12/12          BMI ↓, VLDL ↓, AUC of insulin ↓                                                                                                                                 no side effect is found   ([@B277])
  Artichoke leaf extract                                      RCT      metabolic syndrome                                1800mg po qd            12 weeks               33/35          no significant in blood pressure, FPG, HOMA-IR ↓                                                                                                                no side effect is found   ([@B46])
  Silybum marianum (L). Gaertn. (silymarin) extract           RCT      type 2 diabetes mellitus                          140mg po tid            45 days                20/20          FPG ↓, serum insulin ↓, HOMA-IR ↓, triglyceride ↓, HDL-C ↓                                                                                                      no side effect is found   ([@B47])
  Green coffee extract                                        RCT      metabolic syndrome                                400mg po bid            8 weeks                22/21          FBS ↓, weight ↓, systolic blood pressure ↓, HOMA-IR ↓                                                                                                           no side effect is found   ([@B190])

AUC, area under the curve; APN, adiponectin; BMI, body mass index; BBT, basal body temperature; DHEA-S, dehydroepiandrosterone-sulphate; FSH, follicle stimulating hormone; FINS, fasting insulin; FPG, fasting blood glucose; FPI, fasting plasma insulin; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment of insulin resistance; HbA1c, fasting glycosylated hemoglobin A1c; ISI, insulin sensitivity index; LH, luteinizing hormone; NGT, normal glucose tolerance; PRL, prolactin; QUICKI, quantitative insulin sensitivity check index; S%, SBP, systolic blood pressure; insulin sensitivity; T, testosterone; TG, triglyceride; WC, waist circumference; WHR, waist to hip ratio; 2h INS, postprandial 2 h insulin; 2h PG, 2 hours plasma glucose; ALT, alanine aminotransferase; AST, aspartate aminotransferase.

###### 

Changes in insulin resistance evaluation indicators before and after treatment in clinical trials.

  -------------------------------------------------------------------------------------------------------------------------------------------------------
  Compounds/formula                                              HOMA-IR^1^, AUC of insulin^2^, IRS^3^, QUICKI^4^   Baseline difference             
  -------------------------------------------------------------- -------------------------------------------------- --------------------- --------- -----
  JTTZ Formula^1^                                                T: 1.58 ± 0.72\                                    T: 1.39 ± 0.68\       0.01      NSD
                                                                 C: 1.5 ± 0.75                                      C: 1.35 ± 0.67                  

  Tangyiping Granules (TYP)^1^                                   T: 4.02 ± 0.46\                                    T: 3.59 ± 0.31\       \<0.05    NSD
                                                                 C: 3.87± 0.36                                      C: 3.83 ± 0.37                  

  Jinlida (JLD)^1^                                               T: 2.4(2.0,4.0)\                                   T: 2.41(1.7,3.9)\     0.029     NSD
                                                                 C: 2.5(2.1,3.0)                                    C: 3.0(2.1,3.3)                 

  Qingxue Dan (QXD)^1^                                           T: 164 ± 93\                                       T: 150 ± 92\          \>0.05    NSD
                                                                 C: 226 ± 160                                       C: 205 ± 184                    

  Artemisia dracunculus^2^                                       T: 56,136 ± 27,426\                                T: 44,472 ± 23,370\   \<0.05    NSD
                                                                 C: 92,430 ± 55,920                                 C: 94,278 ± 43,230              

  Qingre Yangyin Recipe (QRYYR)^1^                               T: 3.48 ± 2.03\                                    T: 2.83 ± 1.52\       \<0.05    NR
                                                                 C: 3.81  ± 2.75                                    C: 2.69 ± 1.16                  

  Sancaijiangtang powders^1^                                     T: 6.0 ± 0.8\                                      T: 4.6 ± 1.3\         \<0.05    NSD
                                                                 C: 5.8 ± 1.2                                       C: 3.5 ± 0.8                    

  Cinnamon^1^                                                    T: 8.82 ± 6.59\                                    T: 5.58 ± 3.20\       0.013     NSD
                                                                 C: 7.06 ± 5.65                                     C: 5.8 ± 1.2                    

  Jinlida^1^                                                     T: 1.32 ± 0.79\                                    T: 1.2 ± 0.66\        0.824     NSD
                                                                 C: 1.41 ± 0.79                                     C: 1.31 ± 0.67                  

  Zhenggan Tang decoction^3^                                     T: 1.68 ± 0.21\                                    T: 0.92 ± 0.18\       \<0.05    NSD
                                                                 C: 1.72 ± 0.32                                     C: 1.69 ± 0.44                  

  Marjoram tea^1^                                                T: 1.53(0.18)\                                     T: 1.14(0.14)\        0.06      NSD
                                                                 C: 1.5(0.25)                                       C: 1.68(0.28)                   

  xin-ju-xiao-gao-fang (XJXGF)^1^                                T: 8.10 ± 5.32\                                    T: 5.48 ± 1.05\       0.77      NSD
                                                                 C: 7.84 ± 5.18                                     C: 9.57 ± 1.45                  

  Yiqi Huaju Recipe (YHR)^1^                                     T: 6.01 ± 4.05\                                    T: 4.07 ± 2.80\       \<0.05    NSD
                                                                 C: 6.50 ± 4.15                                     C: 6.63 ± 4.02                  

  Ginger (GG)^4^                                                 T: 0.316 ± 0.025\                                  T: 0.337± 0.303\      \<0.005   NSD
                                                                 C: 0.324 ± 0.031                                   C: 0.333 ± 0.031                

  Curcumin^1^                                                    T: 6.12(2-24.1)\                                   T: 5.92(1.4-14.9)\    \<0.01    NSD
                                                                 C: 5.63(1.4-14.9)                                  C: 2.75(0.9-10.9)               

  Hydroalcoholic extract of *Juglans regia* (walnut) leaves^1^   T: 3.3 ± 2.7\                                      T: 2.9 ± 2.2\         0.186     NSD
                                                                 C: 3.0 ± 1.7                                       C: 2.7 ± 1.4                    

  Yangxin Tongmai Formula (YTF)^1^                               T: 6.48 ± 1.05\                                    T: 4.86 ± 0.54\       \<0.05    NR
                                                                 C: 4.26 ± 0.74                                     C: 4.86 ± 0.69                  

  Sancai powder^1^                                               T: 3.2 ± 0.6\                                      T: 0.8 ± 0.5\         \<0.05    NSD
                                                                 C: 3.4 ± 0.6                                       C: 0.7 ± 0.5                    

  *Fraxinus excelsior* L. seeds/fruits extract^1^                T: 5.65(2.68)\                                     T: 6.86(5.17)\        \>0.05    NSD
                                                                 C: 5.32(3.15)                                      C: 6.05(3.36)                   

  Berberine^2^                                                   T: 92,056 ± 72,148\                                T: 67,407 ± 46,441\   \<0.01    NSD
                                                                 C: 67,605 ± 18,730                                 C: 86,852 ± 57,863              

  Aloe vera gel complex^1^                                       T: 3.4 ± 1.6\                                      T: 3.1 ± 0.2\         \<0.01    NSD
                                                                 C: 3.3 ± 1.2                                       C: 3.5 ± 0.2                    

  Green tea extract^1^                                           T: 5.4 ± 3.9\                                      T: 3.5 ± 2.0\         0.004     NSD
                                                                 C: 5.9 ± 4.5                                       C: 4.7 ± 3.4                    

  Cinnamon^1^                                                    T: 2.7 ± 2.0\                                      T: 1.7 ± 0.7\         \<0.001   NSD
                                                                 C: 3.0 ± 1.2                                       C: 3.0 ± 0.0                    

  Soybean leaf extracts (SLEs)^1^                                T: 1.08 ± 0.06\                                    T: 0.92 ± 0.12\       \<0.05    NSD
                                                                 C: 1.07 ± 0.08                                     C: 1.18 ± 0.08                  

  Nigella sativa^1^                                              T: 3.0 ± 0.24\                                     T: 2.5 ± 0.18\        0.004     NSD
                                                                 C: 2.5 ± 0.17                                      C: 2.51 ± 0.15                  

  Chamomile tea^1^                                               T: 7.05 ± 2.34\                                    T: 4.24 ± 1.95\       \<0.001   NSD
                                                                 C: 5.24 ± 1.23                                     C: 5.55 ± 1.12                  

  DLBS3233^1^                                                    T: 3.00 ± 1.76\                                    T: 2.16 ± 1.17\       0.001     NSD
                                                                 C: 2.76 ± 2.28                                     C: 2.28 ± 1.24                  

  Garlic extract^1^                                              T: 1.89 ± 1.1\                                     T: 1.7 ± 0.9\         0.05      NSD
                                                                 C: 2.5 ± 2.0                                       C: 2.0 ± 1.1                    

  Bee propolis^4^                                                T: 0.37 ± 0.03\                                    T: 0.34 ± 0.03\       \<0.001   NSD
                                                                 C: 0.36 ± 0.03                                     C: 0.03 ± 0.33                  

  Artemisia Extract^1^                                           T: 2.7 ± 1.8\                                      T: 1.7 ± 2.4\         0.031     NSD
                                                                 C: 2.8 ± 1.4                                       C: 4.0 ± 1.5                    

  Red wine polyphenols^1^                                        T: 3.2(2.0, 4.5)\                                  T: 2.9(2.1, 3.8)\     0.72      NSD
                                                                 C: 2.3(1.4, 2.7)                                   C: 2.2(1.5, 2.8)                

  Fresh yellow onion^1^                                          T: 0.052 ± 0.011\                                  T: 0.046 ± 0.006\     0.021     NSD
                                                                 C: 0.045 ± 0.01                                    C:0.051 ± 0.01                  

  Gymnema sylvestre^2^                                           T: 61,626 ± 29,700\                                T: 60,468 ± 37,290\   0.01      NSD
                                                                 C: 64,314 ± 34,914                                 C: 90,816 ± 45,336              

  Artichoke leaf extract^1^                                      T: 3.53(1.44)\                                     T: 3.30(1.47)\        \<0.05    NSD
                                                                 C: 3.11(1.27)                                      C: 3.63(1.55)                   

  Silybum marianum (L). Gaertn. (silymarin) extract^1^           T: 4.25 ± 2.43\                                    T: 2.75 ± 1.19\       0.008     NSD
                                                                 C: 4.49 ± 2.94                                     C: 5.48 ± 3.51                  

  Green coffee extract^1^                                        T: 5.04 ± 3.95\                                    T: 3.62 ± 1.83\       0.024     NSD
                                                                 C: 4.71 ± 2.55                                     C: 5.94 ± 5.16                  
  -------------------------------------------------------------------------------------------------------------------------------------------------------

AT, after treatment; BT, before treatment; C, control group; NR, no reported; NSD, no significant difference; T, treatment group.

\*\*p value: differences in treatment group before and after treatment. "^1^", "^2^", "^3^", "^4^" indicate that the indicators of insulin resistance in the experiment are "HOMA-IR", "AUC of insulin", "IRS" and "QUICKI".

Two evaluators independently assessed the risk of bias in each study and provided the methodological quality of inclusion in clinical trials according to predetermined criteria in the Cochrane Handbook ([**Table 3**](#T3){ref-type="table"}). In general, the methodological quality was assessed to be poor. There are few reports of randomized sequence generation and allocation concealment. Fifteen studies (30/36, 83%) detailed how patients were randomized. Only six trials (6/36, 17%) in this study adequately reported the allocation of hidden methods. Twenty-five trials (25/36, 69%) used blinding on their subjects and investigators. Five trials (5/36, 14%) used blinding on their subjects, investigators, and outcome evaluators. The following restrictions should be considered before accepting the conclusion. First, most of the clinical trials included in this review have certain flaws and bias risks in their methodological design, including the generation of randomization, the concealment of allocation, blinding, and inadequate reporting of sample size estimates. Secondly, the duration of 21 trials (21/36, 58%) was greater than or equal to 12 weeks, and 3 trials (3/36, 8%) lasted longer than 6 months. The impact of duration on the results of the study cannot be ignored. Finally, outcome measures for evaluation of major adverse clinical events, such long-term follow-up, were not considered in this review. Therefore, this review indicates that the evidence for both the benefits and harms of herbal treatment for IR is not strong, and it is necessary to rigorously design further trials with high methodological quality to confirm the conclusion.

###### 

Risk of bias of the clinical trials.

  Compounds/formula                                           A    B    C    D    E    F    G    H    Reference
  ----------------------------------------------------------- ---- ---- ---- ---- ---- ---- ---- ---- -----------
  JTTZ Formula                                                ?    --   --   --   \+   \+   ?    ?    ([@B254])
  Tangyiping Granules (TYP)                                   \+   \+   \+   \+   ?    \+   ?    ?    ([@B85])
  Jinlida (JLD)                                               \+   --   --   --   ?    \+   ?    ?    ([@B206])
  Qingxue Dan (QXD)                                           \+   ?    \+   \+   --   \+   ?    ?    ([@B36])
  Artemisia dracunculus                                       ?    --   \+   \+   --   \+   ?    ?    ([@B158])
  Qingre Yangyin Recipe (QRYYR)                               --   --   \+   --   --   --   ?    ?    ([@B261])
  Sancaijiangtang powders                                     \+   --   \+   --   --   \+   ?    ?    ([@B181])
  Cinnamon                                                    \+   ?    \+   \+   \+   \+   ?    ?    ([@B162])
  Jinlida                                                     \+   \+   \+   \+   \+   \+   --   ?    ([@B134])
  Zhenggan Tang decoction                                     \+   --   --   --   --   \+   ?    ?    ([@B240])
  Marjoram tea                                                \+   --   \+   \+   \+   \+   ?    ?    ([@B64])
  xin-ju-xiao-gao-fang (XJXGF)                                \+   --   \+   \+   --   \+   ?    ?    ([@B271])
  Yiqi Huaju Recipe (YHR)                                     \+   --   \+   --   --   \+   ?    ?    ([@B30])
  Ginger (GG)                                                 \+   --   \+   \+   ?    \+   ?    ?    ([@B164])
  Curcumin                                                    \+   \+   \+   \+   --   \+   ?    ?    ([@B35])
  Hydroalcoholic extract of *Juglans regia* (walnut) leaves   \+   \+   \+   \+   --   \+   ?    ?    ([@B183])
  Yangxin Tongmai Formula (YTF)^1^                            --   --   --   --   --   \+   ?    ?    ([@B149])
  Sancai powder                                               \+   --   \+   --   --   \+   ?    ?    ([@B61])
  *Fraxinus excelsior* L. seeds/fruits extract                ?    \+   \+   \+   \+   \+   ?    ?    ([@B276])
  Berberine                                                   \+   ?    \+   \+   --   \+   ?    ?    ([@B180])
  Aloe vera gel complex                                       \+   --   \+   \+   --   \+   ?    ?    ([@B33])
  Green tea extract                                           \+   ?    \+   \+   --   \+   ?    ?    ([@B136])
  Cinnamon                                                    \+   --   \+   \+   --   \+   ?    ?    ([@B10])
  Soybean leaf extracts (SLEs)                                \+   --   --   --   --   \+   ?    ?    ([@B34])
  Nigella sativa                                              \+   --   \+   --   --   \+   ?    \+   ([@B99])
  Chamomile tea                                               \+   --   \+   --   --   \+   ?    ?    ([@B184])
  DLBS3233                                                    ?    --   \+   \+   --   \+   ?    ?    ([@B151])
  Garlic extract                                              ?    --   \+   \+   --   \+   ?    ?    ([@B11])
  Bee propolis                                                ?    --   \+   \+   --   \+   ?    ?    ([@B196])
  Artemisia Extract                                           \+   --   \+   \+   --   \+   ?    ?    ([@B211])
  Red wine polyphenols                                        \+   --   \+   \+   --   \+   ?    ?    ([@B234])
  Fresh yellow onion                                          \+   --   \+   \+   \+   \+   ?    ?    ([@B88])
  Gymnema sylvestre                                           \+   --   \+   \+   --   \+   ?    ?    ([@B277])
  Artichoke leaf extract                                      \+   --   \+   \+   --   \+   ?    ?    ([@B46])
  Silybum marianum (L). Gaertn. (silymarin) extract           \+   --   \+   \+   --   \+   ?    ?    ([@B47])
  Green coffee extract                                        \+   \+   \+   \+   ?    \+   ?    ?    ([@B190])

A, Adequate sequence generation; B, Concealment of allocation; C, Blinding (patient); D, Blinding (investigator); E, Blinding (assessor); F, Incomplete outcome data addressed (ITT analysis); G, Free of selective reporting; H, Other potential threat to validity; +, Low risk; --, High risk; ?, Unclear.

It must be mentioned that six clinical trials (*Juglans regia* leaves, marjoram tea, *Fraxinus excelsior* L. seeds/fruit extract, garlic extract, bee propolis, and red wine polyphenols) have not confirmed the therapeutic effect of herbs on IR. Possible reasons may include that, firstly, all herbal medicines are not necessarily effective for treating IR while also improving the metabolic index and secondly, these two herbs were not studied using conventional methods of their consuming (they were obtained from extraction using ethanol and soaking in boiling water, respectively). This may have altered the concentration and composition of the drug solution. Despite this, the potential therapeutic effects of herbs on IR are worthy of attention.

Insulin Signal Transduction {#s3_2}
---------------------------

The physiology of insulin involves a complex network of signaling pathways that is activated by the insulin receptor ([@B197]). Insulin binding to an insulin receptor on a cell triggers autophosphorylation followed by phosphorylation of intracellular receptor substrates 1 and 2 (IRS-1/IRS-2) ([@B31]). Several upstream and downstream key signaling molecules in the insulin signaling pathway have been identified, including the phosphoinositide 3-kinase (PI3K)/Akt pathway that is known to be involved in the translocation of glucose transporter 4 (GLUT-4) from intracellular vesicles to cells and promote glucose uptake to adipose tissue and skeletal muscle, eventually decreasing blood glucose levels. Other related pathways include the mitogen-activated protein kinase (MAPK), adenosine monophosphate-activated protein kinase (AMPK), and stress-activated c-Jun-N-terminal kinase (JNK) pathways ([@B18]), among others, and these key players in signal transduction processes are potential targets for drug interventions in IR. IR is characterized by multiple defects, with decreases in receptor concentration and kinase activity, PI3K activity ([@B6]), the concentration and phosphorylation of IRS-1 and IRS-2 ([@B74]), and glucose transporter translocation ([@B23]). Previous studies have found that abnormalities in insulin signaling pathways caused by lipid metabolism disorders, inflammatory responses, oxidative stress, endoplasmic reticulum stress, and mitochondrial dysfunction lead to IR ([@B60]; [@B213]; [@B62]; [@B176]; [@B209]). Metabolic disorder and inflammation cause IR and promote leukocytes to secrete proinflammatory cytokines, including IL-6 and tumor necrosis factor-α (TNF-α) ([@B50]; [@B228]; [@B229]), which provides a framework to understand how physiological stress, obesity, and diet promote IR. We have placed the experimental research on the treatment of IR by herbal medicine into three categories: active ingredients ([**Table 4**](#T4){ref-type="table"}), natural product ([**Table 5**](#T5){ref-type="table"}), and herbal formula ([**Table 6**](#T6){ref-type="table"}). The active ingredient is a relatively single component, and research has proven to play a major role in the therapeutic effects of herbal medicine. The active ingredients listed in [**Table 4**](#T4){ref-type="table"} are berberine, ginsenoside, astragaloside, polydatin, baicalin, maslinic acid, paeoniflorin, *Lycium barbarum* polysaccharide, dihydromyricetin, atractylenolide, etc. Natural products are also extracted from herbs, but the ingredients are relatively complex. The herbs involved in the natural products in the table include mulberry leaves, *Coptis chinensis*, litchi seed, red ginseng, and *Gastrodia elata* Blume. There are many herbs involved in herbal formulas. Some of these herbs have been used frequently, such as *C. chinensis*, mulberry leaves, *Pueraria montana* lobata, *Salvia miltiorrhiza*, and *Astragalus membranaceus*. Therapeutic targets for these herbs include: insulin receptor substrate, phosphatidylinositol 3-kinase, glucose transporter, AMP-activated protein kinase (AMPK), glycogen synthase kinase 3, MAPKs, JNK, nuclear factor-kappaB (NF-κB), protein tyrosine phosphatase 1B, nuclear factor-E2-related factor 2, and peroxisome proliferator-activated receptors. The results suggest that herbal interventions for IR are mostly multi-targeted, sometimes interfering with the same target through different pathways. Insulin receptor substrate signals transduction.

###### 

Active ingredients for improving insulin resistance.

  Type                       Model                              Monomer                                                   Inducer                                                    Animal/cell                                Major findings                   References
  -------------------------- ---------------------------------- --------------------------------------------------------- ---------------------------------------------------------- ------------------------------------------ -------------------------------- ------------
  *In vivo* and *in vitro*   Insulin resistance                 Baicalin                                                  Diet-induced                                               Mice and 3T3-L1 cell                       p38 MAPK, Akt, GLUT4             ([@B49])
  *In vivo*                  Diabetic myocardial hypertrophy    Polydatin                                                 STZ                                                        Mice                                       NF-κB, PPARβ                     ([@B83])
  *In vivo* and *in vitro*   Diabetic and insulin resistance    Polydatin                                                 High-fat and -sugar diet and streptozocin, palmitic acid   Rat and HepG2 cell                         Akt, GSK-3β, IRS                 ([@B68])
  *In vivo* and *in vitro*   Insulin resistance                 *Lycium barbarum* polysaccharide (LBP)                    High-fat diet                                              HepG2 cells and C57BL/6J mice              PI3K/Akt, Nrf2, GSK3β, JNK       ([@B248])
  *In vivo* and *in vitro*   Adiposity and insulin resistance   Maslinic acid (MA)                                        High-fat diet                                              C57BL/6J mice and HepG2 cells              Akt, GSK3β                       ([@B139])
  *In vivo*                  Insulin resistance                 LBP-4a                                                    --                                                         OLETF rats                                 PI3K, p38 MAPK, GLUT4            ([@B266])
  *In vitro*                 Insulin resistance                 Paeoniflorin                                              --                                                         3T3-L1 adipocytes                          IRS-1, Akt                       ([@B111])
  *In vivo*                  Obesity                            Berberine                                                 High-fat diet                                              Rats                                       IRS-1                            ([@B137])
  *In vivo*                  Obesity                            Berberine                                                 High-fat diet                                              Mice                                       AMPK                             ([@B224])
  *In vivo*                  Natural aging                      Berberine                                                 --                                                         Rats                                       p-AMPK                           ([@B255])
  *In vitro*                 Insulin resistance                 Astragaloside IV                                          Glucose + insulin                                          HepG2 cells                                AMPK                             ([@B222])
  *In vitro*                 Insulin resistance                 Astragaloside IV                                          Palmitate                                                  C2C12 myotubes                             IRS1, Akt                        ([@B273])
  *In vivo* and *in vitro*   Obesity/insulin resistance         Ginsenoside Rb2                                           High-fat diet/TNF-α                                        Mice/3T3-L1 adipocytes                     IRS-1, PI3K/Akt, MAPK            ([@B41])
  *In vivo*                  Obesity                            Ginsenoside Rg3                                           High-fat diet                                              C57BL/6 mice/3T3-L1 pre-adipocyte cell     PPAR                             ([@B122])
  *In vivo*                  Insulin resistance                 Ginsenoside Re                                            High-fat diet                                              C57BL/6 mice                               JNK                              ([@B108])
  *In vivo*                  Obesity                            Ginsenoside Rg5                                           High-fat diet                                              ICR mice                                   JNK                              ([@B238])
  *In vivo*                  Insulin resistance                 Dihydromyricetin (DMY)                                    High-fat diet                                              Male Sprague--Dawley (SD) rats             GLUT1, AMPK                      ([@B120])
  *In vitro*                 Insulin resistance                 Atractylenolide I (AT-I) and atractylenolide II (AT-II)   LY294002                                                   Mouse skeletal muscle, C2C12 cells         GLUT4, AMPK, PI3K/Akt            ([@B28])
  *In vivo* and *in vitro*   Insulin resistance                 Fudan-Yueyang Ganoderma lucidum (FYGL)                    --                                                         ob/ob mice, L6 rat skeletal muscle cells   PTP1B, PI3K/Akt, GLUT4, IRS-1,   ([@B249])
  *In vitro*                 Insulin resistance                 α-Methyl artoflavanocoumarin (MAFC)                       Insulin                                                    HepG2 cells                                PTP1B, PI3K/Akt, IRS-1,          ([@B98])
  *In vitro*                 Insulin resistance                 Anthocyanins from Purple Corn                             DMEM                                                       3T3-L1 Adipocytes                          PPARγ, IRS-1, GLUT4, Akt         ([@B147])
  *In vitro*                 Insulin resistance                 Geniposide                                                RPMI-1640 medium                                           HepG2 cells                                NF-κB, GLUT-4                    ([@B92])
  *In vivo*                  Insulin resistance                 Tartary buckwheat flavonoid fraction (TBF)                High fructose                                              Mice                                       Nrf2, GLUT-4, IRS-1,             ([@B82])
  *In vitro* and *in vivo*   Insulin resistance                 Pectic bee pollen polysaccharide (RBPP-P)                 High glucose and fatty acids/high-fat diet                 HepG2 cells/mice                           AMPK                             ([@B130])
  *In vitro*                 Insulin resistance                 Fucosterol                                                --                                                         HepG2 cells                                PTP1B                            ([@B97])
  *In vitro* and *in vivo*   Insulin resistance                 Mulberry anthocyanin extract (MAE)                        High glucose plus palmitic acid                            HepG2 cells/db/db mice                     PI3K/Akt                         ([@B242])
  *In vitro*                 Insulin resistance                 Tartary buckwheat flavonoids (TBF)                        High glucose                                               HepG2 cells                                MAPK, Nrf2, IRS-1,               ([@B81])
  *In vivo*                  Insulin resistance                 Corosolic acid                                            High-fat diet                                              C57BL/6 mice                               IRS-1, AMPK, Akt                 ([@B244])
  *In vivo*                  Insulin resistance                 1-Deoxynojirimycin (DNJ)                                  --                                                         db/db mice                                 PI3K/Akt, GLUT-4, IRS-1          ([@B140])
  *In vivo*                  Insulin resistance                 Rutin                                                     S961                                                       C57BL/6 mice                               GLUT4                            ([@B79])
  *In vitro*                 Insulin resistance                 Total phenolic fraction of *Anemarrhena asphodeloides*    Macrophage-derived conditioned medium                      Adipocytes                                 AMPK                             ([@B267])

###### 

Natural product that improves insulin resistance.

  Type                       Model                                         Natural product                                                                 Inducer                                            Animal/cell                            Major findings                    References
  -------------------------- --------------------------------------------- ------------------------------------------------------------------------------- -------------------------------------------------- -------------------------------------- --------------------------------- ------------
  *In vitro*                 Insulin resistance                            Oligonol                                                                        SF-MEM                                             HepG2 cells                            PTP1B, IRS-1, PI3K/Akt, NF-κB     ([@B20])
  *In vivo*                  Type 2 diabetic mellitus                      Sang-Tong-Jian (STJ)                                                            High-fat diet                                      KKAy mice                              PI3K/Akt, GLUT2, GLUT4, IRS1      ([@B113])
  *In vitro*                 Insulin resistance                            Marein                                                                          High glucose                                       HepG2 cells                            IRS-1, Akt, GLUT1, GSK-3β, AMPK   ([@B90])
  *In vivo*                  Metabolic syndrome                            The fermented Red ginseng and Red ginseng extracts                              High-fructose diet                                 Rats                                   IRS-1, GlUT4                      ([@B106])
  *In vivo*                  Insulin resistance                            Mulberry leaf extract and its Formulation                                       BW and high-energy diet                            SD rats                                IRS-1, JNK                        ([@B142])
  *In vivo*                  Insulin resistance                            *Parkinsonia aculeata* (Caesalpineaceae)                                        High-fat diet                                      Mice                                   AMPKα                             ([@B7])
  *In vivo*                  Insulin resistance                            The fruit of *Acanthopanax senticosus* (Rupr. et Maxim). Harms                  High-fat diet                                      Mice                                   AMPK                              ([@B194])
  *In vitro*                 Type 2 diabetic mellitus                      *Nymphaea nouchali* Burm. f. (Family - Nymphaeaceae)                            MDI                                                3T3-L1 adipocytes                      PPARγ, GLUT4                      ([@B174])
  *In vivo*                  Type 2 diabetic mellitus                      *Cordyceps militaris* number 1 (CmNo1)                                          High-fat diet                                      Mice                                   IRS-1, Akt, GLUT4                 ([@B253])
  *In vitro*                 Insulin resistance e                          6α-Hydroxylup-20(29)-en-3-on-28-oic acid (1)                                    Dexamethasone (DXM)                                3T3-L1 adipocytes                      PI3K/Akt, GLUT4                   ([@B182])
  *In vivo*                  Insulin resistance and hyperlipidemia         Ergostatrien-3β-ol (EK100)                                                      High-fat diet                                      C57BL/6J mouse                         GLUT4, AMPK                       ([@B117])
  *In vitro*                 Insulin resistance                            Coptidis Rhizoma extracts (CRE)                                                 Tumor necrosis factor-α                            3T3-L1 adipocytes                      PPAR-γ, IRS-1                     ([@B256])
  *In vivo*                  Metabolic syndrome                            *Gastrodia elata* Blume (EGB)                                                   High-fructose diet                                 Rats                                   AMPK                              ([@B105])
  *In vivo*                  Adipose dysfunction and insulin resistance    *Cyclocarya paliurus* leaves extracts (CPE)                                     Mac-CM                                             Mice                                   IRS-1, Akt                        ([@B91])
  *In vivo* and *in vitro*   Diabetic                                      *Oroxylum indicum* Vent. (OI)                                                   STZ                                                Rats and 3T3-L1 adipocytes             GLUT4                             ([@B208])
  *In vivo*                  Diabetic                                      *Citrus sinensis* fruit peel (CSMe)                                             High-fat diet and STZ                              Rats                                   PPARγ, GLUT4                      ([@B200])
  *In vivo*                  Type 2 diabetic mellitus                      *Nardostachys jatamansi* DC extract (NJE)                                       Pelletized commercial chow diet                    C57BL/KsJ-db/db mice                   AMPK                              ([@B251])
  *In vivo* and *in vitro*   Type 2 diabetic mellitus                      Catalpol                                                                        High-fat diet and STZ/glucosamine administration   C57BL/6J mice/HepG2 cells              PI3K/Akt, AMPK                    ([@B243])
  *In vivo*                  Insulin resistance                            Ethyl acetate fraction (EAF)                                                    High-fat diet, STZ,nicotinamide                    Rats                                   IRS1, Akt                         ([@B171])
  *In vivo* and *in vitro*   Obesity                                       Epigallocatechin-3-Gallate-Rich Green Tea Extract                               High-fat diet                                      Male c57BL/6 mice/HepG2 cells          AMPK                              ([@B13])
  *In vivo*                  Type 2 diabetic mellitus                      *M. charantia* ethanol extracts (MCE)                                           High-fat diet, streptozotocin (STZ)                Rats                                   JNK, GLUT4                        ([@B150])
  *In vivo* and *in vitro*   Insulin resistance                            Caffeic acid phenethyl ester (CAPE)                                             --                                                 Mice and HepG2 Cell                    JNK, NF-κB, IRS1                  ([@B169])
  *In vivo*                  Type 2 diabetic mellitus                      Aged garlic extract (AGE)                                                       --                                                 Tsumura Suzuki mice                    AMPK                              ([@B159])
  *In vivo* and *in vitro*   Insulin resistance/type 2 diabetic mellitus   Sea buckthorn fruit oil is rich in palmitoleic acid (POA)                       --                                                 HepG2 cells/SD rats                    PI3K/Akt, GSK-3β                  ([@B53])
  *In vitro*                 Insulin resistance                            *Opuntia ficus-indica* var. *saboten* (OFS)                                     DMEM                                               L6 muscle cells                        AMPK, p38 MAPK, GLUT4             ([@B124])
  *In vivo*                  Obesity                                       *P. grandiflorus* root ethanol extract (PGE)                                    High-fat diet                                      C57BL/6J mice                          PPARα, PPARγ,                     ([@B109])
  *In vivo*                  Obesity                                       *Parkinsonia aculeata* (HEPa/EtOAc)                                             High-fat diet                                      C57BL/6J mice                          AMPK                              ([@B7])
  *In vivo* and *in vitro*   Insulin resistance                            Rhizoma Anemarrhenae extract (TFA)                                              STZ                                                Mice/3T3-L1 and Hela cells             AMPK                              ([@B66])
  *In vivo* and *in vitro*   Insulin resistance                            Toona Sinensis leaf (TSL)                                                       High-fat diet/AS160                                Mice/C2C12 myotubes                    AMPK, PPARγ                       ([@B138])
  *In vitro* and *in vivo*   Type 2 diabetes mellitus                      Fumosorinone (FU)                                                               --                                                 HepG2 cells/KKAy mice                  IRS2, Akt, GSK3β, PTP1B           ([@B144])
  *In vitro* and *in vivo*   Insulin resistance                            Ginseng berry extract (GBD)                                                     DMEM                                               C57BL/6 mice/C2C12 cell                PPARγ. IRS1, Akt                  ([@B246])
  *In vivo*                  Type 2 diabetes mellitus                      Bitter melon (BM; Momordica charantia)                                          High-fat diet                                      OLETF rats                             NF-κB, JNK                        ([@B202])
  *In vivo*                  Obesity                                       *Ginkgo biloba* extract (GbE)                                                   High-fat diet                                      Rats                                   IRS1, PTP1B                       ([@B16])
  *In vivo*                  Metabolic syndrome                            Zingiber officinale                                                             High-fat high-carbohydrate diet                    Rats/L6 skeletal muscle cells          AMPK                              ([@B131])
  *In vitro* and *in vivo*   Insulin resistance                            *M. koenigii* (MK)                                                              High-fat diet                                      Mice/L6 skeletal muscle cells          GLUT4, Akt                        ([@B173])
  *In vivo*                  Obesity                                       *Artemisia scoparia* (SCO) and *Artemisia santolinifolia* (SAN)                 High-fat diet                                      C57BL/6J mice                          PPARγ                             ([@B186])
  *In vitro*                 Insulin resistance                            Cinnamon extract (CE)                                                           --                                                 3T3-L1 adipocytes and C2C12 myocytes   AMPK                              ([@B204])
  *In vivo*                  Obesity                                       Extracts of *Artemisia santolinaefolia* (SANT) and *Artemisia scoparia* (SCO)   High-fat diet                                      C57/B6J mice                           AMPK                              ([@B226])

###### 

Herbal formula that improves insulin resistance.

  Type                       Model                                                     Herbal formula                                        Inducer                                                 Animal/cell                           Major findings                      References
  -------------------------- --------------------------------------------------------- ----------------------------------------------------- ------------------------------------------------------- ------------------------------------- ----------------------------------- ------------
  *In vivo*                  Type 2 diabetic mellitus                                  SGY preparation                                       High-fat diet and STZ                                   db/db mice                            PI3K/Akt, IRS-1, GLUT4              ([@B239])
  *In vivo*                  Type 2 diabetic mellitus                                  Dai-Zong-Fang                                         −                                                       db/db mice                            Akt, IRS-1, AMPK, GLUT4             ([@B272])
  *In vitro*                 Insulin resistance                                        Zengye Decoction (ZYD)                                Insulin-induced                                         HepG2 cells                           AMPK                                ([@B145])
  *In vivo*                  Diabetic                                                  Jia-Wei-Jiao-Tai-Wan (JWJTW)                          STZ and a high-sucrose-high-fat diet                    Rats                                  IRS, PI3K, GLUT4                    ([@B29])
  *In vivo*                  Insulin resistance and nonalcoholic fatty liver disease   Seyoeum (SYE)                                         High-fat diet                                           C57BL/6 mice                          IRS-1, IRS-2                        ([@B165])
  *In vitro*                 Insulin resistance                                        Wu-Mei-Wan                                            Palmitate                                               HepG2 cells                           PI3K/Akt, GLUT4, IRS                ([@B247])
  *In vivo* and *in vitro*   Type 2 diabetic mellitus                                  Preparation JQ-R                                      Palmitic acid                                           KKAy mice and cells                   NF-κB, PI3K/AKt, JNK, MAPK          ([@B141])
  *In vivo*                  Type 2 diabetic mellitus                                  Fenugreek seed and mulberry leaf                      High-fat diet and alloxan                               Rats                                  GLUT4                               ([@B104])
  *In vivo* and *in vitro*   Insulin resistance                                        Erchen Decoction and Linguizhugan Decoction           High-fat diet                                           Rats                                  NF-κB, IRS-1                        ([@B259])
  *In vivo*                  Chronic partial sleep deprivation, obesity-resistant      Jiao-Tai-Wan (JTW)                                    High-fat, high-energy diet, environmental noise         SD rats                               NF-κB                               ([@B275])
  *In vivo*                  Metabolic syndrome                                        Modified lingguizhugan decoction                      High-fat diet                                           Rat                                   Akt                                 ([@B250])
  *In vivo*                  Type 2 diabetic mellitus                                  Jiang Tang Xiao Ke (JTXK) granule                     High-fat diet and STZ                                   KKAy mice                             PI3K/Akt, IRS-1, GLUT4, GSK3β       ([@B252])
  *In vivo*                  Insulin resistance                                        Jiangzhi Capsule                                      Liquid fructose                                         Rats                                  GLUT4, Akt                          ([@B93])
  *In vivo*                  Type 2 diabetes mellitus                                  Liuwei Dihuang decoction                              High-fat diets and STZ                                  SD rats                               PI3K/Akt, IRS2                      ([@B40])
  *In vivo*                  Type 2 diabetic mellitus                                  ZiBu PiYin Recipe (ZBPYR)                             High-fat diets and STZ                                  Rat                                   GSK3β                               ([@B212])
  *In vivo*                  Insulin resistance                                        Jinlida                                               High-fat diet                                           Mice                                  IRS-1                               ([@B94])
  *In vivo*                  Polycystic ovary syndrome                                 Shouwu Jiangqi Decoction (SJD)                        Sodium sulfate prasterone, high-fat diet                SD rats                               IRS-1, PI3K                         ([@B223])
  *In vivo*                  Pre-diabetic                                              Tang-Nai-Kang (TNK)                                                                                           Rats                                  AMPK, PPARγ                         ([@B128])
  *In vivo*                  Insulin resistance                                        Jinlida (JLD)                                         High-fat diet                                           Rats                                  JNK, p38MAPK                        ([@B143])
  *In vitro*                 Insulin resistance                                        Modified Si-Miao-San (mSMS)                           Conditioned medium derived from activated macrophages   3T3-L1 adipocytes                     NF-κB, AMPK, PI3K, IRS-1            ([@B245])
  *In vivo*                  Diabetic atherosclerosis                                  Gal-geun-dang-gwi-tang (GGDGT)                        Western diet                                            (ApoE-/-) mice                        IRS-1                               ([@B123])
  *In vivo* and *in vitro*   Insulin resistance                                        Gyeongshingangjeehwan 18 (GGEx18)                     High-fat diet                                           C57BL/6J mice and 3T3-L1 adipocytes   AMPK, PPARα                         ([@B170])
  *In vivo* and *in vitro*   Insulin resistance                                        Salvia-Nelumbinis naturalis (SNN)                     HC diet                                                 HepG2 cells and rats                  Akt, IRS                            ([@B258])
  *In vivo*                  Insulin resistance                                        Kangen-karyu and Salviae Miltiorrhizae Radix          −                                                       Rats                                  PI3K/Akt, p38MAPK, NF-κB            ([@B175])
  *In vivo*                  Polycystic ovarian syndrome                               Bushen Huatan Recipe (BHR)                            Dehydroeplandrosterone                                  Rats                                  Akt, GSK-3β, GLUT4, IRS-1, PPAR-γ   ([@B76])
  *In vivo* and *in vitro*   Metabolic syndrome                                        Fu Fang Zhen Zhu Tiao Zhi formula (FTZ)               High insulin and high-fat diet                          HepG2 cells and rats                  PI3K, IRS-1                         ([@B80])
  *In vivo*                  Type 2 diabetic mellitus                                  Fructus Mume formula and its separated prescription   High-fat diet and STZ                                   Rats                                  IRS-1, GlUT-4                       ([@B127])
  *In vivo*                  Insulin resistance                                        Refined-JQ (JQ-R)                                     High-fat diet                                           C57BL/6J mice                         AMPK                                ([@B52])
  *In vivo*                  Type 2 diabetes mellitus                                  TZQ-F                                                 High-fat diet                                           KKA(y) mice                           PPARγ, IRS-1, IRS-2, GLUT1, PI3K    ([@B166])
  *In vivo*                  Type 2 diabetes mellitus                                  Jiaotai Pill (JTP)                                    STZ and high fat diet                                   Rats                                  PI3K, IRS-1, GLUT4                  ([@B45])
  *In vivo*                  Polycystic ovary syndrome                                 Heqi San                                              Dehydroepiandrosterone                                  Female SD rats                        PI3K/Akt, GLTU4                     ([@B264])
  *In vivo*                  Type 2 diabetes mellitus                                  Fructus Mume formula                                  High-fat diet and STZ                                   Rats                                  IRS-1, GLUT4                        ([@B127])

Insulin Receptor Substrate Signal Transduction {#s3_3}
----------------------------------------------

The insulin receptor belongs to the subfamily of receptor tyrosine kinases, including insulin-like growth factor 1 receptors and insulin receptor-related receptors ([@B230]). Most insulin signals promote or regulate phosphorylation of IRS-1 or its homolog IRS-2 *via* tyrosine ([@B63]), and IRS-1 is the major substrate of the insulin receptor. IRS mediates insulin action differently in different tissues, with IRS-1 playing a prominent role in skeletal muscle and IRS-2 in the liver ([@B107]). Studies have shown that liver IRS-1 and IRS-2 have complementary effects in controlling liver metabolism; IRS-1 is more closely related to glucose homeostasis ([@B24]), and IRS-2 is more closely related to lipid metabolism ([@B217]). Insufficient expression of IRS-1 and IRS-2 can lead to IR ([@B215]; [@B207]). Jinlida particles can raise insulin sensitivity in skeletal muscle in fat-induced insulin-resistant ApoE-/- mice by increasing the expression of IRS-1 mRNA and protein ([@B94]). Treating high insulin-induced HepG2 cells with FTZ *in vitro* upregulated the expression of IRS-1 protein while attenuating *in vitro* glucose levels ([@B80]). Abnormal phosphorylation of IRS is also an important mechanism of IR.

IRS1 and IRS2 appear to lack intrinsic catalytic activity but contain many serine and tyrosine phosphorylation sites ([@B230]). Serine/threonine phosphorylation of IRS-1 at the phosphorylation site Ser307 may inhibit insulin signaling ([@B191]) and attenuate tyrosine phosphorylation levels ([@B192]). Salvia-Nelumbinis naturalis (SNN) improves hepatic insulin sensitivity in rats and increases IRS phosphorylation ([@B258]). Tumor necrosis factor-α (TNF-α) reduces insulin receptor substrate tyrosine phosphorylation and is an important mediator of IR in obesity and diabetes ([@B78]). Erchen decoction and Linguizhugan decoction reduce the level of TNF-α in diet-induced insulin-resistant rats to improve IR ([@B259]), similar to the pharmacological action of thiazolidinedione ([@B179]). In addition, degenerative neuropathies such as Alzheimer's disease ([@B214]) and multiple system atrophy ([@B17]) are also closely related to brain IR caused by blocked IRS signaling. Defects in IRS-1 may cause vascular damage and accelerate the progression of atherosclerosis ([@B1]), while IRS-2 delays neointimal formation under IR ([@B115]). Gal-geun-dang-gwi-tang attenuates endothelial dysfunction by promoting nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) signaling and improves insulin sensitivity in individuals with diabetic atherosclerosis. Gal-geun-dang-gwi-tang was also shown to be associated with restored expression of IRS-1 in the thoracic aorta and skeletal muscle ([@B123]).

PI3K/Akt Signaling Pathway Signal Transduction {#s3_4}
----------------------------------------------

Glucose is mainly metabolized in insulin-sensitive tissues by two pathways: the classical phosphatidylinositol 3-kinase (PI3K) pathway and the 5'-AMP activating kinase (AMPK) signal transduction pathway ([@B89]). Tyrosine phosphorylation of the insulin receptor substrate activates PI3K, and activated PI3K catalyzes 4,5-2 phosphatidylinositol (PIP2) and produces PIP3, which acts as a second messenger that activates Akt ([@B230]). Activated Akt promotes downstream molecules that regulate metabolism. Liuwei Dihaung decoction can be used to treat IR by regulating the PI3K/Akt signaling pathway in the liver of rats with T2D, accompanied by phosphorylation and upregulation of PI3K/Akt pathway-associated proteins ([@B40]). PI3K is composed of a regulatory subunit p85 and a catalytic subunit p110 ([@B56]) and has dual activities of phosphatidylinositol kinase and serine/threonine (Ser/Thr) protein kinase. Heterozygous mutations in the PI3Kp85 regulatory subunit gene often result in metabolic disorders such as IR associated with decreased ability to activate PI3K in muscle and adipose tissue ([@B233]). Significant damage to PI3K signaling in muscle often results in muscle IR and systemic glucose intolerance ([@B148]). Central glucagon-like peptide 2 can enhance hepatic insulin sensitivity by activating G3-2R-p85a interactions in PI3K signaling in proopiomelanocortin neurons ([@B205]). Different proportions of Jiaotai Pill enhance PI3K pathway insulin signaling by upregulating the expression of the PI3K p85 subunit in skeletal muscle, attenuating the development of diabetes in a rat model of T2D ([@B45]). Akt has three isoforms, of which Akt1 and Akt2 are highly expressed in skeletal muscle and have unique and overlapping functions ([@B155]). Overexpression of Akt1 is associated with increased beta cell size and total islet mass ([@B220]), and Akt2 is more important for insulin-stimulated glucose metabolism ([@B24]). Defects in signaling pathways caused by mutations in the protein kinase *Akt2/PKB gene* often impair the ability of insulin to lower blood glucose in the liver and skeletal muscle ([@B58]). Paeoniflorin improves TNF-α-induced IR in adipocytes and is associated with insulin-stimulated Akt phosphorylation recovery in adipocytes ([@B111]). Akt2 is involved in glucose uptake by insulin-regulated muscle and adipocytes by promoting the transport of GLUT-4 to the cell surface ([@B168]), as is metformin, which also increases liver Akt phosphorylation and promotes GLUT-4 translocation ([@B55]). Jiangzhi capsule improved fructose-induced IR and repaired the damaged muscle fiber membrane GLUT-4 cycle by regulating the ratio of phosphorylated Akt to total Akt in the gastrocnemius muscle ([@B93]). Akt2 is required for hepatic lipid accumulation in obese and insulin-resistant states induced by leptin deficiency or high-fat diet (HFD) ([@B121]). Modified lingguizhugan decoction improves liver fat accumulation and IR in rats with metabolic syndrome by inhibiting abnormal increases in leptin and PKB in the liver ([@B250]).

Glucose Transporters Signal Transduction {#s3_5}
----------------------------------------

There are currently 13 known sugar transporter proteins (GLUT1-12 and HMIT) encoded in the human genome ([@B96]). Based on sequence similarity and characteristic elements, the extended GLUT family can be divided into three subfamilies, of which class I contains the glucose transporters GLUT1-4, which all show tissue/cell specific expression ([@B235]). GLUT-4 is highly expressed in adipose tissue and skeletal muscle ([@B23]). The main cellular mechanism for handling exogenous glucose load is insulin-stimulated glucose transport into skeletal muscle, and the primary glucose transporter that mediates this uptake is GLUT-4 ([@B84]). Oxidative stress caused by overnutrition often induces GLUT-4 inactivation by carbonylation and oxidation ([@B22]), and related gene variants ([@B210]) often lead to GLUT-4 deficiency and downregulation in skeletal muscle and adipose tissue ([@B274]; [@B2]). Exercise and caloric restriction can upregulate GLUT-4 gene expression and increase insulin-induced GLUT-4 transport to the plasma membrane ([@B187]; [@B257]). A novel botanical formula containing standardized extracts of mulberry leaf, fenugreek seed, and American ginseng can attenuate the decrease in GL UT-4 expression induced by an HFD and alloxan ([@B104]). A key step in the physiological role of GLUT-4 is translocation ([@B15]), in which GLUT-4 is redistributed from the intracellular pool to the plasma membrane under the regulation of the Akt substrate AS160 rab GTPaseactivating protein ([@B198]). Studies have shown that cold exposure therapy can significantly increase GLUT-4 translocation in basal skeletal muscle and may be a potential treatment for diabetes ([@B67]). *Oroxylum indicum* stem bark extract significantly enhanced insulin sensitivity in mature 3T3-L1 adipocytes, as evidenced by increased skeletal muscle GLUT-4 translocation ([@B208]). GLUT-2 is mainly found in the liver, intestine, kidney, and pancreatic beta cells ([@B235]), and it plays an important role in glucose transport and energy metabolism because it promotes glucose uptake or liver efflux ([@B218]). Sang-Tong-Jian, a new formulation of flavonoids and alkaloids from mulberry leaves, improves IR in KKAy mice, which is associated with upregulation of GLUT-2 (liver) gene, and protein expression ([@B113]). GLUT-1 is expressed at the highest level in the endothelial tissues of barrier tissues such as blood vessels and blood-brain barriers, and moderate levels of expression are also observed in adipose tissue, muscle, and liver, which play an important role in supplying glucose to organs such as the brain ([@B43]; [@B216]). Chinese herbal formula TZQ-F treatment upregulates the expression of related proteins such as GLUT-1, which regulates the potency of insulin action and is beneficial for reducing hyperinsulinemia ([@B166]).

AMP-Activated Protein Kinase Signal Transduction {#s3_6}
------------------------------------------------

AMPK is a conserved, ubiquitously expressed heterotrimeric serine/threonine protein kinase ([@B101]) that plays a key role in regulating cellular energy metabolism ([@B118]). AMPK integrates nutrient and hormonal signals in peripheral tissues and the hypothalamus and is regulated by multiple hormones such as leptin, adiponectin, ciliary neurotrophic factor, and ghrelin ([@B161]; [@B227]; [@B265]). AMPK plays an important role in regulating food intake, body weight, glucose, and lipid metabolism ([@B160]). In addition, AMPK can also be activated in response to cellular stress, exercise ([@B26]), and drugs ([@B199]). Based on traditional Chinese medicine, Dai-Zong-Fang improves insulin sensitivity in db/db diabetic mice by inhibiting liver lipids and enhancing energy metabolism in skeletal muscle by inhibiting AMPK activation ([@B272]). Under physiological conditions, AMPK is mainly present in an inactive form complexed with Mg-ATP, which is more abundant than AMP ([@B237]). An increase in AMP concentration activates AMPK, and by phosphorylating the activation loop within the kinase domain ([@B132]), AMPK transitions from an inactive form to a catalytic form: binding of AMP to the c-regulatory domain promotes phosphorylation of the upstream kinase and causes allosteric activation, and inhibition of the dephosphorylation of Thr172 in the kinase domain activation loop regulates AMPK phosphorylation levels ([@B236]). Goka fruit supplements improve IR and liver lipid accumulation in mice with HFD-induced obesity by increasing AMPK phosphorylation in the liver. AMPK in adipocytes is critical for maintaining mitochondrial integrity, responding to pharmacological agents and heat stress, and protecting against nutrient overload-induced NAFLD and IR ([@B110]; [@B163]). Modified Si-Miao-San positively regulates AMPK phosphorylation to promote basal glucose uptake by 3T3-L1 adipocytes and beneficially improves insulin signaling by inhibiting inflammation in adipocytes ([@B245]). Adiponectin is a major insulin-sensitized adipokine ([@B100]). It has been shown that adiponectin and its receptors AdipoR1 and AdipoR2 enhance glucose and fatty acid metabolism by activating AMPK in peripheral tissues ([@B114]). The herbal composition GGEx18 can treat visceral obesity and visceral obesity-related IR by upregulating visceral fat expression of fatty acid oxidation genes. The results show that the expression of fatty acid oxidation genes, including genes encoding adiponectin, AMPK, and others, is significantly increased in mesenteric adipose tissue of 3T3-L1 adipocytes and obese mice ([@B170]).

Glycogen Synthase Kinase 3 Signal Transduction {#s3_7}
----------------------------------------------

GSK-3 is a ubiquitous cytosolic serine/threonine protein kinase expressed in mammalian tissues as two closely related isoforms: GSK-3α and GSK-3β ([@B42]). GSK-3 is constitutively active under resting conditions and regulates human metabolism through phosphorylation of glycogen synthase and other substrates ([@B103]). Inhibition of GSK-3 is required for insulin-stimulated glycogen and protein synthesis, and its inhibition is critical for the normal functioning of insulin-activated signaling pathways ([@B4]). The skeletal muscle GSK-3 activity and its expression level were significantly increased in patients with T2D ([@B195]), and abnormally excessively elevated GSK-3 resulted in further inhibition of glycogen synthase activity. A large body of evidence indicates that GSK-3 inhibitors have therapeutic uses in neurodegenerative diseases, cancer, and T2D ([@B178]; [@B86]; [@B153]). Jiangtangxiaoke granules are an effective drug for T2D, since this treatment can regulate the expression of glycogen synthase kinase 3β (GSK3β) by regulating the PI3K/Akt signaling pathway in skeletal muscle of mice with T2D ([@B252]). Insulin-induced GSK-3 inhibition is mediated through its downstream target protein kinase B (PKB), which phosphorylates and inactivates GSK-3 at Ser9/21 ([@B37]; [@B51]). ZiBu PiYin recipe treatment alters insulin signaling in T2DM rats in association with inhibited GSK3β overexpression resulting from increased p-GSK3β levels in the pre-frontal cortex and hippocampus ([@B212]). Abnormal overactivity of GSK-3 may also limit IR-mediated signaling through phosphorylation of IRS-1. Polydatin significantly increased phosphorylated GSK-3β and increased protein levels of phosphorylated IRS in liver and insulin-resistant HepG2 cells of diabetic rats ([@B68]). Therefore, GSK-3 inhibitors can be a promising new drug for diabetic IR.

P38 Mitogen-Activated Protein Kinase Signal Transduction {#s3_8}
--------------------------------------------------------

MAPKs and their downstream targets are important signaling modules for cellular responses to changes in the physical and chemical properties of the environment ([@B38]). It is known that MAPK has at least four subfamilies in mammalian cells: p38 kinase (p38α, β, γ, and δ), extracellular signal-regulated kinase (ERK1/2), ERK5, and Jun amino terminal kinase (JNK1-3) ([@B57]). Insulin activates the PI3K/Akt pathway, which is responsible for glucose uptake, and the MAPK pathway, which is critical for IR ([@B195]). MAPK is involved in a variety of processes that control hepatic metabolism ([@B119]). Obesity and inflammation-related stress responses in insulin-responsive tissues activate liver MAPKs, which are thought to impair insulin action and lipid metabolism ([@B77]). MAPK phosphatases (MKPs) can dephosphorylate MAPK to catalyze the inactivation of MAPK ([@B57]). Baicalin plays an important role in reversing HFD-induced glucose intolerance and IR in diet-induced obese mice, and its mechanism is associated with downregulation of p-p38 MAPK levels ([@B49]). Reactive oxygen species (ROS)-mediated activation of p38MAPK stress response signaling has been recognized as one of the causes of insulin signaling damage and hepatic IR ([@B5]). Jinlida, a compound preparation based on traditional Chinese medicine, can attenuate oxidative stress and reduce phosphorylation of p38MAPK and JNK in high-fat fed rats, showing antioxidant effects and upregulation of insulin signaling ([@B143]).

C-Jun-N-Terminal Kinase Signal Transduction {#s3_9}
-------------------------------------------

The JNK is a member of the MAPK family, and three JNK isoforms exist in mammals: JNK1, JNK2, and JNK3 ([@B119]). JNK1 and JNK2 are expressed in almost all celRls, including liver parenchymal cells, while JNK3 is mainly expressed in the brain, heart, and testis ([@B201]). Cytokines, ROS, endoplasmic reticulum stress, and free fatty acids activate JNK ([@B172]; [@B75]; [@B263]) and play a key role in metabolic disorders such as obesity, IR, and T2D ([@B221]). *Lycium barbarum* polysaccharide treatment effectively inhibits phospho-JNK levels in HFD-fed mice and reduces ROS levels *via* the PI3K/AKT/Nrf2 axis, acting as a novel anti-hyperlipide-induced IR oxidizer ([@B248]). Stress factors such as non-esterified fatty acids are generally thought to induce inhibitory serine phosphorylation of IRS-1 through the JNK pathway and impair insulin signaling ([@B73]; [@B54]). Studies have also confirmed that hepatocyte-specific deletion of JNK1 enhances IR ([@B193]). Therefore, JNK may positively regulate hepatic insulin signaling, and in other insulin-sensitive organs, JNK negatively regulates insulin action, especially under stress conditions. This is the potential protective effect of mulberry leaf extract (MLE) and a formula consisting of MLE, fenugreek seed extract, and cinnamon cassia extract (MLEF) on hyperglycemia induced by high-energy diet and toxic chemicals in rats and recovery of insulin sensitivity, the most likely mechanism is the upregulation of phosphorylation of JNK and other related proteins in the liver to promote IRS-1 phosphorylation ([@B142]).

Nuclear Factor-kappaB Signal Transduction {#s3_10}
-----------------------------------------

NF-κB is a sequence-specific transcription factor that is a major regulator of inflammatory responses, including responses to inflammation and oxidative stress ([@B32]). In the quiescent state, NF-κB binds to the inhibitor subunit IκB in an inactive form in the cytoplasm. IKK-β is required for activation during acute inflammation. Phosphorylation-activated IKKβ induces phosphorylation of IκB kinase α ([@B8]) and IκBα phosphorylates IκB and leads to proteolysis of IκB, which exposes nuclear recognition sites for NF-κB. NF-κB is translocated into the nucleus, resulting in the expression of related target genes such as inflammatory cytokines ([@B25]). Thus, blocking NF-κB signaling improves IR and prevents the development of diabetes ([@B225]). Jiao-Tai-Wan, composed of Rhizome Coptidis and Cortex Cinnamomi, reversibly increases markers of systemic inflammation and IR caused by sleep loss in Sprague-Dawley rats, and these changes are related to downregulation of NF-κB mRNA expression in peripheral blood mononuclear cells ([@B275]). NF-κB may represent an attractive therapeutic target for obesity, IR, diabetes, and other complications associated with these diseases.

Protein Tyrosine Phosphatase 1B Signal Transduction {#s3_11}
---------------------------------------------------

Protein tyrosine phosphatase 1B belongs to the protein tyrosine phosphatase (PTP) family ([@B219]) and has a catalytic domain characterized by an 11 amino acid sequence motif containing cysteine (Cys215) and arginine (Arg221) ([@B69]). These residues are critical to the catalytic activity of the enzyme. As a negative regulator of the insulin signaling cascade, PTP1B overexpression inhibits tyrosine phosphorylation of IR and IRS-1, enhances serine phosphorylation, thereby terminating insulin signaling ([@B95]). Oligonol, a low molecular weight polyphenol mixture derived from lychee fruit, can significantly reduce PTP1B expression and reduce serine phosphorylation of IRS-1, improving insulin sensitivity in insulin-resistant HepG2 cells ([@B20]). In general, PTP1B inhibitors are a promising class of insulin sensitizers.

Nuclear Factor-E2-Related Factor 2 Signal Transduction {#s3_12}
------------------------------------------------------

Nuclear factor erythrocyte 2-related factor 2 (Nrf2) is a key regulator of antioxidant signaling and plays a crucial role in maintaining redox homeostasis ([@B203]). Under physiological conditions, Nrf2 remains in the cytoplasm by binding to the endogenous inhibitor Keap1, which mediates rapid activation of the proteasome and subsequent degradation of Nrf2 ([@B262]). Under exogenous and endogenous oxidative stress, Nrf2 becomes stable and released from the Keap1/Nrf2 complex, Nrf2 degradation is inhibited, and Nrf2 accumulates in the nucleus, synergistically enhancing the expression of various genes encoding antioxidant enzymes ([@B19]). Many studies have shown that increased Nrf2 signaling can inhibit oxidative stress and improve insulin and leptin resistance ([@B241]). *L. barbarum* polysaccharide, an antioxidant from wolfberry, increases Nrf2 phosphorylation in livers of HFD-fed mice and HepG2 cells by inducing PI3K/AKT signaling and induces Nrf2/ARE signaling to reduce oxidative stress and maintain peripheral insulin sensitivity ([@B248]).

Peroxisome Proliferator-Activated Receptor Signal Transduction {#s3_13}
--------------------------------------------------------------

Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors involved in the transcriptional control of genes encoding proteins involved in adipocyte differentiation, lipid and carbohydrate metabolism, and adipokine synthesis, including three isoforms encoded by different genes ([@B48]). PPARα is highly expressed in liver, kidney, and skeletal muscle. PPARγ is also highly expressed in various cell types and organs, including fat cells, muscle cells, liver, and kidneys, and is considered to be a major regulator of glucose homeostasis ([@B65]). Studies have suggested that the production of future PPARα and γ double agonists will simultaneously bring about favorable changes in PPARα lipid mass spectrometry and blood glucose benefits of PPARγ agonists ([@B154]). The existing insulin-sensitizing drug thiazolidinedione is a potent agonist of nuclear PPAR-γ ([@B71]). Based on the traditional anti-diabetic formula, TZQ-F can improve IR in KKA(y) mice through its efficacy in regulating adipocyte differentiation and insulin action, and the results indicate that its therapeutic effect is related to the upregulation of PPARγ expression in liver tissue ([@B166]) and PPARγ coactivator 1α (PGC1α), which is a PPAR-mediated transcriptional coactivator of fatty acid oxidation ([@B112]). Tang-Nai-Kang is a mixture of five herbal plant extracts that has been shown to improve glucose metabolism abnormalities in patients with pre-diabetes. Tang-Nai-Kang treatment can deacetylate PGC1α to activate it and synergize with PPAR expression to enhance fatty acid oxidation and improve insulin levels in rats ([@B128]).

Conclusions and Perspectives {#s4}
============================

IR is a pathological condition common to many metabolic diseases; the most well known of which is T2D. Some surveys show that China is one of the countries with the highest incidence of T2D in the world, and the number of people with diabetes in the adult population have exceeded 113.9 million in 2010 ([@B269]). The global trend of other metabolic diseases associated with IR is also not optimistic. From 2003 to 2012, the overall prevalence of metabolic syndrome in the United States was 33% ([@B3]). It is estimated that nearly 100 million people in the United States have NAFLD ([@B189]). Global Burden of Disease studies have shown that the prevalence of obesity has doubled in 73 countries between 1980 and 2015 ([@B87]). In addition, based on the 1990 National Institutes of Health standard, PCOS affects 6--10% of women worldwide ([@B59]), and studies have indicated that 56.3% of Han women in China with PCOS have IR ([@B129]). Therefore, in the face of such a large potential patient population, the harm caused by IR cannot be ignored. Herbs have been used in China for more than 2,000 years and are still considered effective drugs to prevent and treat various diseases. The discovery and application of artemisinin, a compound derived from *Artemisia annua*, is a good example. In recent years, research on Chinese medicine has gradually been standardized and systematized. China's latest guidelines for preventing and treating T2D are also the first to include Chinese medicine treatment.

The information presented in this review shows that herbal formulas, active ingredients, and natural products can be effective to improve IR. Targets of herbal compounds that affect insulin signaling include insulin receptor substrate, phosphatidylinositol 3-kinase, glucose transporter, AMPK, glycogen synthase kinase 3, MAPKs, JNK, NF-κB, protein tyrosine phosphatase 1B, nuclear factor-E2-related factor 2, and peroxisome proliferator-activated receptors.

In [**Table 7**](#T7){ref-type="table"}, we have listed the composition of the above herbal formula in detail. In addition, we have found that certain herbs have a good application prospect in the treatment of IR. Such single botanicals include Coptis, Pueraria, Mulberry, Salvia, and others. Effective extracts of herbal medicines include berberine and mulberry leaves. There are also effective active ingredients such as berberine, ginsenoside, astragaloside, and resveratrol. The effects of these drugs are not only limited to enhancing insulin sensitivity, but also can be beneficial for improving systemic metabolism, such as reducing fasting blood glucose and postprandial blood glucose, improving blood lipid metabolism, reducing body weight, lowering blood pressure, and regulating female hormone secretion. Therefore, the role of herbal medicine in the treatment of IR is not only beneficial for treating T2D, but also provides new ideas for treating obesity, metabolic syndrome, PCOS, and NAFLD.

###### 

Composition of herbal formula.

  ----------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  JTTZ formula                                          *Aloe vera*, *Coptis chinensis*, *Rhizoma Anemarrhenae*, red yeast rice, *Momordica charantia*, *Salvia miltiorrhiza*, *Schisandra chinensis*, *Zingiber oj-jicinale Rosc.*
  Tangyiping granules (TYP)                             *Astragalus mongholicus* 30 g, *Paeoniae Radix Alba* 12 g, *Coptis chinensis* 15 *g*, *Salvia miltiorrhiza* 12 g, *Pinellia ternate* 9 *g*, *Pueraria lobata* 30 g.
  Jinlida (JLD)                                         *Panax ginseng C. A. Mey.*, *puerarin*, *pale white atractylodes rhizome*, *Coptis chinensis*, *poria cocos*, *radix polygonati officinalis*, and so on
  Qingxue Dan (QXD)                                     *Scutellaria baicalensis Georgi*, *Coptis chinensis Franch.*, *Platycladus orientalis (Linn). Franco*, *Gardenia jasminoides Ellis*, *Rhizoma of Rheum palmatum Linne*
  Qingre Yangyin Recipe (QRYYR)                         *Cortex Lycii*, *Rehmannia glutinosa Libosch*, *Ophiopogon japonicus (Linn. f). Ker-Gawl.*,*Cynanchum otophyllum*, *Salvia miltiorrhiza*,*Poria cocos(Schw).Wolf*, *Acorus tatarinowii*, *Alisma plantago-aquatica Linn.*, *Lycium barbarum L.*,*Cuscuta chinensis Lam.*,*Epimedium sagittatum*, *Rubus idaeus L.*
  Sancaijiangtang powders                               *Panax Ginseng*,*Asparagus Racemosus*, *Radix*, *Rehmanniae*,dark plum fruit, *Cortex*, *Cinnamomi*, *Rhizoma Coptidis*,
  Jinlida                                               *Panax ginseng C. A. Mey.*, *Fallopia multiflora (Thunb). Harald*, *Atractylodes lancea (Thunb). DC*, *Sophora flavescens*, *Ophiopogon japonicus (Linn. f). Ker-Gawl.*, *Rehmannia glutinosa Libosch*, *Fallopia multiflora (Thunb). Harald*, *Cornus officinalis Sieb. et Zucc.*, *Poria cocos (Schw). Wolf*, *Eupatorium fortunei Turcz.*,*Coptis chinensis Franch.*, *Anemarrhena asphodeloides Bunge*, *Epimedii Folium*, *Salvia miltiorrhiza Bge.*, *Pueraria thomsonii Benth*, *Litchi chinensis Sonn.*, *Cortex Lycii*
  Zhenggan Tang decoction                               *Pseudostellaria heterophylla (Miq). Pax ex Pax et Hoffm.*, *Atractylodes macrocephala Koidz.*, *Astragalus mongholicus Bunge*, *Poria cocos (Schw). Wolf*, *Angelica sinensis (Oliv). Diels*, *Salvia miltiorrhiza Bge.*, *Trionyx sinensis Wiegmann*, *Radix Bupleuri*, *Cynanchum otophyllum*
  xin-ju-xiao-gao-fang (XJXGF)                          *Rheum palmatum L.*, *Coptis chinensis Franch.*,*Cassia tora Linn.*, *Citrus aurantium L.*
  Yiqi Huaju Recipe (YHR)                               *Astragali Radix 10 g*, *Coptis chinensis Franch.* 3*g*, *Typha angustifolia L.* 10*g*, *Artemisia capillaris Thunb* 10 g, *Alisma plantago-aquatica Linn.* 10 g
  Yangxin Tongmai Formula (YTF)                         *Radix Ginseng* 10*g*, *Radix Salviae Miltiorrhizae* 15*g*, *Ramulus Cinnamomi* 6*g*, *Fructus Aurantii Immaturus* 10*g*, *Rhizoma Alismatis* 10 g
  Sancai powder                                         *Radix Ginseng*, *Radix Asparagi*, *Cochinchinensis*, *Radix Rehmanniae*, *Rhizoma Coptidis*, *Cortex Cinnamomi Cassiae*, *Fructus Mume*
  SGY preparation                                       *Morus alba L.*, *Pueraria thomsonii Benth (Leguminous)*, *Dioscoreae rhizoma (Dioscoreaceae)*, *Momordica charantia L.*
  Dai-Zong-Fang                                         *Rhizoma Coptidis*, *Fructus Aurantii Immaturus*
  Zengye Decoction (ZYD)                                *Radix Scrophulariae*, *Radix Rehmanniae*, *Radix Ophiopogonis*
  Jia-Wei-Jiao-Tai-Wan (JWJTW)                          *Cinnamomum cassia*, *Rhizoma coptidis*, *Astragalus membranaceus*, *Herba Gynostemmatis*, *Radix Puerariae Lobatae*, *Folium Mori*, *Semen Trigonellae*
  Seyoeum (SYE)                                         *Coix lacryma-jobi*, *Oryza sativa*, *Sesamum indicum*, *Glycine max*, *Liriope platyphylla*, *Dioscorea batatas*
  Wu-Mei-Wan                                            *Lycium barbarumL.*, *Angelica dahurica (Fisch. ex Hoffm.)Benth. et Hook. f. ex Franch. et Sav*, *Zingiber oj-jicinale Rosc.*,*Rhizoma coptidis*, *Angelica sinensis (Oliv). Diels*, *Ziziphus jujuba Mill.*, *Zanthoxylum bungeanum Maxim.*,*Cinnamomum cassia*, *Panax ginseng C. A. Mey.*, *Platycladus orientalis (Linn). Franco*
  Preparation JQ-R                                      *Rhizoma Coptidis*, *Astragalus membranaceus*, *Lonicera japonica*
  Fenugreek seed and mulberry leaf                      *Morus alba L.*, *Trigonella foenum-graecum L.*, *Panax quinquefolius L.*
  Erchen Decoction and Linguizhugan Decoction           *Pinellia ternata*, *Pericarpium Citri Reticulatae*, *Poria cocos (Schw). Wolf*, *Glycyrrhiza uralensis Fisch.*/*Poria cocos*, *cassia twig*, *Rhizoma Atractylodis Macrocephalae*, *and licorice*
  Jiao-Tai-Wan (JTW)                                    *Rhizome Coptidis*, *Cortex Cinnamomi*
  Modified lingguizhugan decoction                      *Poria cocos (Schw). Wolf*, *Cinnamomum cassia Presl*, *Atractylodes lancea (Thunb). DC.*, *Glycyrrhiza uralensis Fisch.*, *Codonopsis pilosula (Franch). Nannf.*, *d Rheum palmatum L*
  Jiang Tang Xiao Ke (JTXK) granule                     *Radix rehmanniae*, *Fructuscorni*, *Radix salviae miltiorrhizae*, *Rhizoma coptidis*, *Radix Puerariae Lobatae*, *etc.*
  Jiangzhi Capsule                                      *Radix Astragali*, *Poria cocos (Schw). Wolf*, *Folium Nelumbinis*, *Rhizoma Alisma*, *Fructus Crataeg*, *Fructus Chaenomelis*, *Radix et Rhizoma Salviae Miltiorrhizae*, *Radix et Rhizoma Notoginseng*, *Pollen Typhae*, *Rhizoma et Radix Polygoni cuspidate*, *Herba Taraxaci*, *Radix Polygoni multiflori*, *Fructus Ligustri Lucidi*
  Liuwei Dihuang decoction                              *Rehmannia glutinosa Libosch*, *Cornus officinalis Sieb*, *Dioscorea opposite Thunb*, *Alisma orientale Juz*, *Poria cocos Wolf*, *Paeonia suffruticosa Andrews*
  ZiBu PiYin Recipe (ZBPYR)                             Red Ginseng, *Common Yam Rhizome*, *Poria cocos (Schw). Wolf*, *Cynanchum otophyllum*, *Salvia miltiorrhiza Bge.*, *Dolicho Lablab L.*, *Nelumbo nucifera Gaertn.*, *Acorus tatarinowii*, *Polygala tenuifolia Willd.*, *Santalum album linn*, *Pericarpium Citri Reticulatae*, *Glycyrrhiza uralensis Fisch.*
  Jinlida                                               *Panax ginseng C. A. Mey.*, *puerarin*, *pale white atractylodes rhizome*, *Coptis chinensis*, *poria cocos*, *radix polygonati officinalis*, *etc.*
  Shouwu Jiangqi Decoction (SJD)                        *Fallopia multiflora (Thunb).*, *Harald*, *Astragalus membranaceus (Fisch).*, *Bunge.*, *roasted Bombyx Batryticatus*, *Common Yam Rhizome*, *Euonymus alatus (Thunb). Sieb.*, *Cyperus rotundus L.*, *etc.*
  Tang-Nai-Kang (TNK)                                   *Fructus Ligustri Lucidi*, *Prunella vulgaris L.*, *Saururus chinensis (Lour). Baill*, *Psidium guajava Linn.*, *Panax ginseng C. A. Mey.*
  Jinlida (JLD)                                         *Panax ginseng C. A. Mey.*, *Polygonatum sibiricum*, *Atractylodes Lancea (Thunb). DC.*, *Sophora flavescens*, *Ophiopogon japonicus (Linn. f). Ker-Gawl.*, *Rehmannia glutinosa Libosch*, *Fallopia multiflora (Thunb). Harald*, *Cornus officinalis Sieb. et Zucc.*, *Poria cocos (Schw). Wolf.*, *Eupatorium fortunei Turcz.*, *Coptis chinensis Franch.*, *Anemarrhena asphodeloides Bunge*, *Epimedium brevicornu Maxim.*, *Salvia miltiorrhiza Bge.*, *Pueraria thomsonii Benth*, *Litchi chinensis Sonn.*, *Cortex Lycii*
  Modified Si-Miao-San (mSMS)                           *Coptis chinensis Franch.*, *Phellodendron amurense Rupr.*, *Semen Coicis*, *Atractylodes Lancea (Thunb). DC.*
  Gal-geun-dang-gwi-tang (GGDGT)                        *Pueraria thomsonii Benth*, *Glycyrrhiza uralensis Fisch.*, *Angelica sinensis (Oliv). Diels*, *Ophiopogon japonicus (Linn. f). Ker-Gawl.*, *Cynanchum otophyllum*, *Cornus officinalis Sieb. et Zucc.*, *Chaenomeles sinensis (Thouin) Koehne*, *Rehmannia glutinosa Libosch*, *Nelumbo nucifera Gaertn*, *Dark Plum Fruit*, *Schisandra chinensis*, *Anemarrhena asphodeloides Bunge*, *Ligusticum chuanxiong Hort.*, *Asparagus cochinchinensis (Lour.) Merr.*, *Trichosanthes kirilowii Maxim*, *Cyperus rotundus L.*
  Gyeongshingangjeehwan 18 (GGEx18)                     *Laminaria japonica*, *Rheum palmatum L.*, *Ephedra sinica Stapf*
  Salvia-Nelumbinis naturalis (SNN)                     *Salvia miltiorrhiza Bge.*, *Nehlmbo nucifera*,*Reynoutria japonica Houtt.*, *Artemisia capillaris Thunb*
  Kangen-karyu and Salviae Miltiorrhizae Radix          *Cynanchum otophyllum*, *Ligusticum chuanxiong Hort.*, *Carthamus tinctorius L.*, *Cyperus rotundus L. Radix Aucklandiae*, *Salvia miltiorrhiza Bge./Salvia miltiorrhiza Bge.*
  Bushen Huatan Recipe (BHR)                            *Epimedii Folium*, *Curculigo orchioides Gaertn*, *Atractylodes Lancea (Thunb). DC.*, *Pinellia ternata (Thunb). Breit.*,*Pericarpium Citri Reticulatae*, *Acorus calamus L.*, *Cyperus rotundus L.*, *Ligusticum chuanxiong Hort.*, *Alisma plantago-aquatica Linn.*, *Cervus nippon Temminc*, *Arisaema heterophyllum Blume*, *Amomum villosum Lour.*, *etc.*
  Fu Fang Zhen Zhu Tiao Zhi formula (FTZ)               *Fructus Ligustri Lucidi*, *Atractylodes macrocephala Koidz.*, *Salvia miltiorrhiza Bge.*, *Coptis chinensis Franch.*, *Panax notoginseng (Burk). F.H. Chen*, *Eucommia ulmoides*, *Cirsium japonicum Fisch. ex DC*, *Citrus medica L.* var.*sarcodactylis Swingle*
  Fructus Mume formula and its separated prescription   *Prunus mume (Sieb). Sieb. et Zucc.*, *Asarum heterotropoides*, *Zingiberis officinale Rosc*, *Coptidis chinensis Franch*, *Aconitum carmichaelii Debx.*, *Angelicas Sinensis (Oliv). Diels*, *Zanthoxylum bungeanum Maxim.*, *Cinnamomum cassia Presl*, *Panax ginseng C. A. Mey.*, *Phellodendrom chinense Schneid*
  Refined-JQ (JQ-R)                                     *Rhizoma Coptidis*, *Astragalus membranaceus*, *Lonicera japonica*
  TZQ-F                                                 *Morus alba L.*, *Lotus Leaf*,*Salvia miltiorrhiza Bge.*, *Grataegus pinnati fida Bge.*, *Radix paeoniae rubra*
  Jiaotai Pill (JTP)                                    *Coptis chinensis Franch.*, *Cinnamomum cassia Presl*
  Heqi San                                              *Schisandra chinensis (Turcz). Baill.*, *Cynanchum otophyllum C. K. Schneid.*, *Hordeum vulgare L*
  Fructus Mume formula                                  *Prunus mume (Sieb).Sieb. et Zucc.*, *Asarum heterotropoides Fr. Schmidt* var.*mandshuricum*, *Zingiberis officinale Rosc*, *Coptidis chinensis Franch*, *Aconitum carmichaelii Debx.*, *Angelicas Sinensis (Oliv). Diels*, *Zanthoxylum bungeanum Maxim.*, *Cinnamomum cassia Presl*, *Panax ginseng C. A. Mey.*, *Phellodendrom chinense Schneid*
  ----------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

However, there were some shortcomings in our research. First, most of the interventions studied were herbal formulas and extracts. The diversity of ingredients in the herbal formulas and extracts results in complex potential therapeutic mechanisms. Not only does it make understanding the role of drugs difficult, but it also makes in-depth research impossible. However, the existing research also has the same shortcomings as our research. In addition, there are studies questioning the role of herbal medicine in the treatment of IR. The beneficial effects of ginsenosides on IR are listed in [**Table 4**](#T4){ref-type="table"}, but clinical trials have shown that oral ginseng or ginsenosides do not improve insulin sensitivity in glucose-tolerant or obese/overweight subjects who are newly diagnosed with diabetes ([@B185]). However, the clinical trial lasted only 8 weeks, and in most *in vitro* and *in vivo* tests, ginsenosides were administered by intraperitoneal injection. In clinical trials, the systemic utilization and metabolic processes have to be considered only after oral administration. Studies have indicated that ginsenoside is a precursor. The pharmacological action of ginsenoside is to activate intestinal deglycosylation and fatty acid esterification ([@B70]). Therefore, the *in vitro* and *in vivo* levels of ginsenosides should not be the only focus of the trial.

In response to these shortcomings, we can make some improvements in future studies. For example, regarding the bioavailability of herbal medicines, we can use targeted drug delivery systems (TDDSs) to improve the way in which the active ingredients of herbal medicines are administered. Research on targeted preparations related to TDDSs has become a popular topic, especially for applications in the field of anti-cancer research. Targeted administration can be divided into liposomes, granules, nanoparticles, emulsions, and other similar preparations ([@B126]). The combination of drugs and specific target carriers can play a synergistic and attenuating role. At present, research on herbal drug delivery systems is still in the exploration stage, and the design, synthesis, and quality evaluation of TDDS are more suitable for single herbal ingredients. Therefore, separating the active ingredients of herbs is particularly important, including those known or unknown. We can select safe and effective single herbs from the many herbal formulas obtained from the literature and experimental research and separate the active ingredients, such as monomers, by pharmacological methods. Then, based on the active ingredients of the herbal medicine, the effective target mechanism of the drug can be studied. Finally, the active ingredient, target, and TDDS are combined. This not only makes the research on herbal medicine more targeted and efficient, but also provides a good prospect for the development and application of anti-insulin drugs.

Author Contributions {#s5}
====================

JL and LB designed the work of review. JL, LB, and FW reviewed the literature available on this topic and wrote the paper. JZ, DW, YX, and WY contributed in the scientific writing of the manuscript. JL, LB, and JW revised the manuscript. All authors approved the paper for publication. JL, LB, FW, JZ, DW, YX, and WY contributed equally to this work. JL and LB contributed equally to this study and share first authorship.

Funding {#s6}
=======

This paper was supported by Central Health Research Project W2017BJ43.

Conflict of Interest Statement {#s7}
==============================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

[^1]: Edited by: Alejandro Urzua, Universidad de Santiago de Chile, Chile

[^2]: Reviewed by: Susan Semple, University of South Australia, Australia; Yun K. Tam, Sinoveda Canada Inc., Canada

[^3]: This article was submitted to Ethnopharmacology, a section of the journal Frontiers in Pharmacology
